A breakthrough therapy, Atrial Flow Regulator (AFR), discovered by Occlutech, is designed for heart failure patients with preserved (HFpEF) or reduced (HFrEF) ejection fraction.
The AFR upholds an interatrial shunt by a predetermined diameter which allowsfor a controlled blood flow from the left to the right atrium thus lowering the left atrial pressure. Reduced left atrial pressure has been shown toreduce heart failure symptoms and improve exercise tolerance.
First-in-class, implantable Atrial FlowRegulator (AFR) for heart failure (HF) patients with preserved (HFpEF) or reduced (HFrEF)ejection fraction has been granted breakthrough device designation.
Heart Failure is a serious condition caused by the inadequate supply of blood supply to the body. Globally, it affects over 30 million people. Its symptoms include fatigue, palpitations, and exertional dyspnea. It disorders results in causing pericardium,myocardium, endocardium, heart valves, great vessels or specific metabolic abnormalities. HF, if left untreated will significantly worsen, resulting in increased morbidity driving to hospitalisations, and higher mortality.
